| 摘要 |
The present disclosure provides a pediatric growth hormone deficiency (PGHD) therapy for pediatric subjects. In some embodiments, the therapy comprises administering to the pediatric patient with PGHD a human growth hormone -XTEN (hGH-XTEN) fusion protein in therapeutically effective doses once a month, two-times a month, three-times a month, or four-times a month, wherein the treatment continues for at least about 3 months from first administration, and wherein the pediatric patient's height velocity does not decline during the treatment. In some embodiments, methods disclosed herein achieve results that are not statistically inferior compared to the height velocity achieved with daily injections of hGH alone over the same period. |
